242 related articles for article (PubMed ID: 24308789)
1. Pediatric formulation issues identified in Paediatric Investigation Plans.
Quijano Ruiz B; Desfontaine E; Arenas-López S; Wang S
Expert Rev Clin Pharmacol; 2014 Jan; 7(1):25-30. PubMed ID: 24308789
[TBL] [Abstract][Full Text] [Related]
2. European perspectives on pediatric formulations.
Breitkreutz J
Clin Ther; 2008 Nov; 30(11):2146-54. PubMed ID: 19108802
[TBL] [Abstract][Full Text] [Related]
3. Paediatric Drug Development and Formulation Design-a European Perspective.
Van Riet-Nales DA; Kozarewicz P; Aylward B; de Vries R; Egberts TC; Rademaker CM; Schobben AF
AAPS PharmSciTech; 2017 Feb; 18(2):241-249. PubMed ID: 27270905
[TBL] [Abstract][Full Text] [Related]
4. Reflection on the Pharmaceutical Formulation Challenges Associated with a Paediatric Investigation Plan for an Off-Patent Drug.
Walsh J
AAPS PharmSciTech; 2017 Feb; 18(2):250-256. PubMed ID: 27097815
[TBL] [Abstract][Full Text] [Related]
5. Eunice Kennedy Shriver National Institute of Child Health and Human Development Pediatrics Formulation Initiative: proceedings from the Second Workshop on Pediatric Formulations.
Giacoia GP; Taylor-Zapata P; Zajicek A
Clin Ther; 2012 Nov; 34(11):S1-10. PubMed ID: 23149008
[TBL] [Abstract][Full Text] [Related]
6. Playing hide and seek with poorly tasting paediatric medicines: do not forget the excipients.
Walsh J; Cram A; Woertz K; Breitkreutz J; Winzenburg G; Turner R; Tuleu C;
Adv Drug Deliv Rev; 2014 Jun; 73():14-33. PubMed ID: 24614069
[TBL] [Abstract][Full Text] [Related]
7. Moving toward a paradigm shift in the regulatory requirements for pediatric medicines.
Chin WW; Joos A
Eur J Pediatr; 2016 Dec; 175(12):1881-1891. PubMed ID: 27646479
[TBL] [Abstract][Full Text] [Related]
8. Pediatric drug development: formulation considerations.
Ali AA; Charoo NA; Abdallah DB
Drug Dev Ind Pharm; 2014 Oct; 40(10):1283-99. PubMed ID: 24483293
[TBL] [Abstract][Full Text] [Related]
9. European Union pediatric legislation jeopardizes worldwide, timely future advances in the care of children with cancer.
Rose K
Clin Ther; 2014 Feb; 36(2):163-77. PubMed ID: 24529288
[TBL] [Abstract][Full Text] [Related]
10. European Paediatric Formulation Initiative (EuPFI)-Formulating Ideas for Better Medicines for Children.
Salunke S; Liu F; Batchelor H; Walsh J; Turner R; Ju TR; Tuleu C;
AAPS PharmSciTech; 2017 Feb; 18(2):257-262. PubMed ID: 27422653
[TBL] [Abstract][Full Text] [Related]
11. More than 5 years of European Paediatric Regulation: statistics and industrial experience.
Winzenburg G
Int J Pharm; 2014 Aug; 469(2):260-2. PubMed ID: 24704106
[TBL] [Abstract][Full Text] [Related]
12. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.
Ceci A; Felisi M; Catapano M; Baiardi P; Cipollina L; Ravera S; Bagnulo S; Reggio S; Rondini G
Eur J Clin Pharmacol; 2002 Nov; 58(8):495-500. PubMed ID: 12451425
[TBL] [Abstract][Full Text] [Related]
13. The economics of pediatric formulation development for off-patent drugs.
Milne CP; Bruss JB
Clin Ther; 2008 Nov; 30(11):2133-45. PubMed ID: 19108801
[TBL] [Abstract][Full Text] [Related]
14. Enabling Development of Paediatric Medicines in Europe: 10 Years of the EU Paediatric Regulation.
Tomasi PA; Egger GF; Pallidis C; Saint-Raymond A
Paediatr Drugs; 2017 Dec; 19(6):505-513. PubMed ID: 28900869
[TBL] [Abstract][Full Text] [Related]
15. Progress review of the European Paediatric Regulatory Framework after six years of implementation.
Mentzer D
Int J Pharm; 2014 Aug; 469(2):240-3. PubMed ID: 24613178
[TBL] [Abstract][Full Text] [Related]
16. Formulations in paediatric investigation plans (PIPs): Introduction to PIP quality section and regulatory framework.
Wang S
Int J Pharm; 2015 Aug; 492(1-2):332-4. PubMed ID: 25959119
[No Abstract] [Full Text] [Related]
17. Determination of formulation factors that affect oral medicines acceptability in a domiciliary paediatric population.
Venables R; Batchelor H; Hodson J; Stirling H; Marriott J
Int J Pharm; 2015 Mar; 480(1-2):55-62. PubMed ID: 25601436
[TBL] [Abstract][Full Text] [Related]
18. Best practices for selection of excipients for paediatrics - Workshop reflection.
Salunke S; Clapham D; Agrawal A; Hughes K; Nunn T
Eur J Pharm Biopharm; 2021 Mar; 160():77-81. PubMed ID: 33400989
[TBL] [Abstract][Full Text] [Related]
19. Formulation approaches to pediatric oral drug delivery: benefits and limitations of current platforms.
Lopez FL; Ernest TB; Tuleu C; Gul MO
Expert Opin Drug Deliv; 2015; 12(11):1727-40. PubMed ID: 26165848
[TBL] [Abstract][Full Text] [Related]
20. Issues impacting therapeutic outcomes in pediatric patients: an overview.
Kalra A; Goindi S
Curr Pediatr Rev; 2014; 10(3):184-93. PubMed ID: 25088338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
